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Abstract
Background: Clinical practice guidelines are an important element of evidence-based practice. Considering an
often complicated body of evidence can be problematic for guideline developers, who in the past may have
resorted to using levels of evidence of individual studies as a quasi-indicator for the strength of a
recommendation. This paper reports on the production and trial of a methodology and associated processes to
assist Australian guideline developers in considering a body of evidence and grading the resulting guideline
recommendations.
Methods: In recognition of the complexities of clinical guidelines and the multiple factors that influence choice in
health care, a working group of experienced guideline consultants was formed under the auspices of the
Australian National Health and Medical Research Council (NHMRC) to produce and pilot a framework to formulate
and grade guideline recommendations. Consultation with national and international experts and extensive piloting
informed the process.
Results: The FORM framework consists of five components (evidence base, consistency, clinical impact,
generalisability and applicability) which are used by guideline developers to structure their decisions on how to
convey the strength of a recommendation through wording and grading via a considered judgement form. In
parallel (but separate from the grading process) guideline developers are asked to consider implementation
implications for each recommendation.
Conclusions: The framework has now been widely adopted by Australian guideline developers who find it to be a
logical and intuitive way to formulate and grade recommendations in clinical practice guidelines.
Background
Best practice in health care should be guided by the
results of research on the safety and effectiveness of dif-
ferent courses of clinical action. This evidence needs to
be assembled, justified and presented in the form of
health advice for multiple stakeholders including health
professionals, decision makers and consumers of health
care. Clinical practice guidelines are recognised as one of
the best ways to present recommended courses of action
based on research evidence, although recommendations
are often presented inconsistently [1]. Where such evi-
dence is not available, guidelines may use consensus-
based practice points and/or identify areas requiring
further research. Both format and content can adversely
affect the adoption and integration of guidelines into
clinical practice [2].
The National Health and Medical Research Council
(NHMRC) of Australia has been a world leader in devel-
oping and supporting the development of evidence-based
health advice, including clinical practice guidelines. As
early as 1999, the NHMRC commissioned and published
‘Guidelines for Guideline Development’ [3], anticipating
the need for a comprehensive set of resources to help
guideline developers produce high quality guidelines.
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on different aspects of finding and reviewing clinical
research [4].
Australian guideline developers must comply with
NHMRC standards in order to gain NHMRC approval.
These standards (such as rigorous evidence-based meth-
ods, multidisciplinary panels and public consultation
processes) have resulted in NHMRC approved guide-
lines being of higher quality than those developed out-
side NHMRC processes [5].
By 2004, it had become clear that the NHMRC stan-
dards required expansion and revision in response to
the rapid growth and diversification of clinical practice
guidelines in Australia and elsewhere. There were two
main areas where a need for revision was identified. The
first was the need to develop a set of levels (or hierar-
chy) of evidence which would cover the different indivi-
dual study designs used to address the different types of
questions formulated by guideline development panels.
This work (covering interventions, diagnostic accuracy,
prognosis, aetiology and screening) is outlined in Merlin
et al [6]. The second area was the need to develop a
new system, or adaptation of an existing system, of for-
mulating and grading recommendations for clinical
practice guidelines that incorporated an assessment of
the ‘body of evidence’.
The concept of a body of evidence
Many guideline recommendations have been rated solely
according to the level of evidence of the individual stu-
dies contributing to that recommendation. In the late
1990 s and early 2000 s, NHMRC prepared a series of
handbooks to assist clinical practice guideline develo-
pers. These handbooks stated that other elements such
as study quality, size and precision of study results, and
relevance to local practice were also important [3,4].
They did not, however, go as far as providing a trans-
parent logical framework for assessing these elements
when formulating recommendations. What was needed
was a method for considering all of these elements
across all of the research studies addressing the clinical
question as a whole (the ‘body of evidence’)l i k es o m e
other guideline developmentm e t h o d o l o g i e s( s u c ha s
t h o s eu s e db yt h eS c o t t i s hI n t e r c o l l e g i a t eG u i d e l i n e s
Network or the National Institute for Health and Clini-
cal Excellence). Recommendations based on the body of
evidence could then be graded according to the degree
of confidence that implementing the suggested course of
action would lead to improved patient health outcomes.
In recognition of this need, and in response to requests
from methodological experts that consult for the
NHMRC on guideline development (Guidelines Assess-
ment Register [GAR] consultants) (see Appendix 1),
the NHMRC undertook to revise and update its
methodological approaches. This paper reports on the
production and trial of a methodology and associated
processes to assist Australian guideline developers in
considering a body of evidence and grading the resulting
guideline recommendations.
Methods
In 2004, the NHMRC commissioned a review of existing
frameworks for assessing evidence internationally [7].
This internal report provided a resource for a working
party (comprising GAR consultants and NHMRC per-
sonnel - see Appendix 1 for members) to review existing
practice, design and/or adapt a framework for grading a
body of evidence and pilot this process with Australian
guideline developers.
The report identified nine possible systems for use in
developing clinical practice guidelines. Of these, three
were considered to be most useful for informing the
development of an Australian guideline recommendation
process. These frameworks were the Scottish Intercol-
legiate Guidelines Network (SIGN) system and consid-
ered judgement statement (SIGN50, revised 2008) [8];
the Strength of Recommendation Taxonomy (SORT) [9];
and the Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) [10].
These systems were discussed at a face-to-face meet-
ing of the working party with respect to their advantages
and disadvantages and compatibility with the existing
advice in the NHMRC ‘Guidelines for Guideline Devel-
opment’ handbooks. A consensus was reached about
how these frameworks could be adapted in the new pro-
cess. From the three systems, we combined elements to
achieve our objectives, which were: to have a system
that matched and complemented the current NHMRC
evidence dimensions and documents as closely as possi-
ble; simplicity and clarity of approach; and to provide
transparent method/s of formulating and documenting
judgments to give a graded set of recommendations.
The working party drafted a new framework for grading
recommendations and this was refined by extensive
email consultation and iteration within the group.
The resulting draft framework was piloted by GAR con-
sultants working with guideline developers between 2005
and 2009. There were five main methods to gather feedback:
￿ Known experts in the international guideline field
were approached by NHMRC directly for comment
on the draft system - this was a formal request and
responses were semi-structured in that the experts
were free to review in their own style,
￿ Key evidence-based assessment organisations in
Australian and New Zealand were invited to register
feedback on the website where the system was
posted,
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the NHMRC endorsement framework during this
period used FORM under the guidance of the GARs
- they were all invited to offer feedback during and
after the process.
￿ The draft process was presented at key conferences
and interactive workshops (eg International
Cochrane Colloquium [11]),
￿ The website was open for the 5 years (passive
seeking) and included a structured feedback form.
Following this initial period of consultation (up until
2007) the FORM’s framework was further refined, taking
account of the feedback received, and the public consul-
tation period was extended to June 2009. During the
development, trialing and refinement period from 2004
to 2009, the international guideline community contin-
ued to debate and evolve other systems of guideline pro-
duction - these developments were monitored and
helped to inform the Australian process. The revised
version of FORM was subsequently endorsed by the
Council of the NHMRC.
Results
The new FORM framework was loosely based on the
SIGN considered judgement form [8]. It provides guide-
line developers with a structured process for considering
the whole body of evidence relevant to a particular clini-
cal question, in the context of the setting in which it is
to be applied. FORM recognises that ascribing a level of
evidence to each study that reflects the risk of bias in its
design, is only one small part of assessing evidence for a
guideline recommendation. FORM provides a frame-
work for assessing all the studies relevant for a recom-
mendation against five criteria: the evidence base (i.e.
number, level and risk of bias in included studies); the
consistency of findings between studies; the clinical
impact suggested by the evidence base; the generalisabil-
ity of the results to the population for whom the guide-
line is intended; and the applicability of the results to
the Australian (and/or local) health care setting. Under
FORM, these five key components are individually
assessed for each clinical question giving a picture of
both the internal and external validity of the evidence
base under consideration.
Key components of FORM
1. Evidence base
T h ee v i d e n c eb a s ei sa s s e s s e di nt e r m so ft h eq u a n t i t y
and quality of the studies identified by a systematic lit-
erature review for the clinical question concerned
(’included studies’). Study quality relates to an assess-
ment of the risk of bias inherent in the conduct, design
and reporting of results in the included studies.
T h eg u i d e l i n ed e v e l o p e r sa r ef r e et oc h o o s et h em o s t
relevant process or tool to assess risk of bias. To ensure
that consideration is given to the full range of study
designs required to assess the breadth of clinical ques-
tions in a guideline, the GAR consultants also developed
levels of evidence to address different clinical questions
(prognosis, diagnostic accuracy, aetiology etc). This has
been comprehensively addressed by Merlin et al [6]
(see also, NHMRC website: http://www.nhmrc.gov.au/
guidelines/developers.htm)
2. Consistency
The consistency component of the ‘body of evidence’
assesses the extent to which the findings are consistent
across the included studies (including across a range of
study populations and study designs). This allows users
to assess whether the results are likely to be replicable
or only likely to occur under certain conditions. Consis-
tency may be assessed where appropriate as statistical
heterogeneity (applying an I-squared statistic for exam-
ple) or more likely will require the users to make a
judgment about the overall direction of effects across
multiple studies with reference to clinical heterogeneity.
Possible sources of inconsistency (heterogeneity) in the
results of studies may be differences in the study design,
the quality of the studies (risk of bias), the population
studied, and varying definitions of outcomes being
assessed. Should results differ for certain subpopula-
tions, this could then be reflected in the development of
the recommendation.
3. Clinical impact
Clinical impact is a measure of the likely benefit that
application of the guideline would have across the target
population, and involves a clinical judgement. Factors
that need to be taken into account when estimating
clinical impact include: the relevance of the evidence to
the clinical question; the statistical precision and size
(and clinical importance) of the effect reported in the
evidence-base; the relevance of the effect to patients,
compared to other management options; the duration of
therapy required to achieve the effect; and the balance
of risks and benefits to the patient group, including
potential harm. A hypothetical example of incorporating
both clinical importance and potential harm may be for
the use of statins in the control of dyslipidaemia where
there is a very large body of evidence with low risk of
bias indicating a substantial reduction in risk of cardio-
vascular events. In this case a qualifying recommenda-
tion could be made to differentiate the small group of
people who may experience adverse events as a result of
statin therapy.
Clinical impact is arguably the most subjective of the
five evidence components rated in the evidence state-
ment. However, we have found in assisting many guide-
line development groups to produce clinical practice
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clearer for clinicians than it is for methodological
experts. Clinicians seem to grasp the net benefit concept
quite easily, although often robust discussions occur
before a consensus is reached regarding the rating of
this component. A strength of FORM is that these
discussions contribute to formulating appropriate
recommendations, and the final conclusion can be docu-
mented so that users of the guideline can see how the
developers arrived at the recommendation.
4. Generalisability
The assessment of generalisability involves determining
how precisely the available body of evidence answers the
clinical question that was asked. Issues to be considered
include: how well the participants and settings of the
included studies match the patient population being tar-
geted by the guideline; the clinical setting where the
recommendation will be implemented; and other factors
such as the stage of the disease (e.g. early versus
advanced), the duration of illness and (for diagnostic
accuracy questions) the prevalence of the disease in the
study population as compared to the target population
for the guideline.
5. Applicability
This component addresses whether the evidence base is
relevant to the Australian health care system generally,
or to more local settings for specific recommendations
(such as rural areas or cities). Factors that may reduce
the direct application of study findings to the Australian
or more local settings include organisational factors (e.g.
availability of trained staff, clinic time, specialised equip-
ment, tests or other resources) and cultural factors (e.g.
attitudes to health issues, including those that may affect
compliance with the recommendation).
The FORM Matrix and Evidence Statement Form
The FORM matrix forms part of the overall process
which is detailed in Additional file 1. Each of the com-
ponents in the FORM matrix can be rated from A to D.
The body of evidence supporting a recommendation
rarely consists of the same rating for each of the five
components. There may be a large number of studies
with a low risk of bias and consistent findings, but
which have only a limited clinical impact, and are not
directly generalisable to the target population or applic-
able to the local (e.g. Australian) healthcare context.
Alternatively, a body of evidence may consist of one or
two randomised trials with small sample sizes that have
a moderate risk of bias but have a very large clinical
impact and are directly applicable to the local healthcare
context and target population. By rating each of the five
components separately, FORM allows for this mixture
of components, while still reflecting the overall body of
evidence supporting a guideline recommendation.
T h eF O R MM a t r i xp r o v i d e sg u i d a n c ef o ru s e r sa b o u t
how to rate each component of the body of evidence
(see Table 1). The accompanying Evidence Statement
Form is provided for guideline developers to complete
for each clinical question with room for additional infor-
mation and dissenting opinions to be recorded.
A recommendation to answer the clinical question is
developed in two stages. First, a rating is assigned for
each of the five components described above and an
evidence statement is written in passive voice to reflect
the findings of the evidence base. Second, an overall
recommendation or action statement is developed on
the basis of the evidence statement and an overall grade
is assigned to this recommendation that reflects the
level of confidence in the evidence supporting the
recommendation.
Evidence statements may be developed by outcome
measures for each intervention and then the multiple
evidence statements for a single question can be col-
lapsed into a single recommendation. Guideline develo-
pers can produce a combined recommendation taking
into account the balance of benefits and harms or sepa-
rate recommendations for benefits and harms, if this is
more appropriate. The FORM process allows consider-
able flexibility in developing the recommendation.
The overall grades for recommendations should indi-
cate the strength of the body of evidence underpinning
the recommendation. This assists users of the clinical
practice guidelines to make appropriate and informed
clinical judgments. Grade A or B recommendations are
g e n e r a l l yb a s e do nab o d yo fe v i d e n c et h a tc a nb e
trusted to guide clinical practice, whereas Grade C or D
recommendations must be applied carefully to individual
clinical and organisational circumstances and should be
interpreted with caution (see Table 2). A recommenda-
tion cannot be graded A or B unless the evidence base
and consistency of the evidence are both rated A or B.
In some cases, lower-graded evidence statements may
not provide sufficient confidence to support an evi-
dence-based recommendation at all. However, the fra-
mework allows Good Practice Points (GPP) to be
included when developers feel it is important to provide
non-evidence-based guidance.
In formulating the recommendation users are advised
to address the specific clinical question and to use
action statements. The wording of the recommendation
should reflect the strength of the body of evidence.
Words such as ‘must’ or ‘should’ or ‘use’ are included
when the evidence underpinning the recommendation is
strong, and words such as ‘might’ or ‘could’ or ‘consider’
are used when the evidence base is weaker.
The following recommendations illustrate these points
and are taken from the NHMRC Clinical Practice
Guidelines for the Management of Melanoma in
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show that the evidence base, consistency and impact
were high for dermoscopy, but not so high for total
body photography (also indicated by the use of the verb
‘recommended’ in the first case and ‘consider’ in the
second):
￿ Training and utilisation of dermoscopy is recom-
mended for clinicians routinely examining pigmen-
ted skin lesions: Grade A;
￿ Consider the use of baseline total body photogra-
phy as a tool for the early detection of melanoma in
patients who are at high risk for developing primary
melanoma: Grade C (p xxii [12]).
Developers are also asked to consider how the guide-
line will be implemented at the time that the guideline
recommendations are being formulated. The Evidence
Statement Form requests developers to consider whether:
the recommendation will result in changes in usual care;
there are any resource implications associated with
implementing the recommendation; the implementation
of the recommendation will require changes in the way
care is currently organised; and the guideline develop-
ment group are aware of any barriers to the implementa-
tion of the recommendation. This information is used to
inform the implementation plan for the Guideline.
Feedback, piloting and users’ experiences
Over the trial and consultancy period for the FORM grad-
ing process, we obtained feedback from invited experts
(see acknowledgements), from current guideline develo-
pers and from the public. These issues and suggestions
were carefully considered at the face-to-face meeting of
the GAR consultants in 2007 (see methods). Where appro-
priate, we amended the FORM methodology and/or sup-
porting documents to incorporate the suggestions or
address problems. This iterative process ensured that the
development of FORM was responsive to the needs of its
core user group - guideline developers - and was as clear
and comprehensible as possible, even for developers with
limited methodological expertise. It also allowed the
FORM development process to keep abreast of the some-
times rapidly changing methodology underpinning guide-
line development internationally and incorporate changes
into FORM as appropriate. As developers of FORM and
also methodological experts assisting guideline developers
we (the authors) have been able to field-test the FORM
process and gain first-hand feedback and direct experience
Table 1 NHMRC Body of evidence matrix
Component A
Excellent
B
Good
C
Satisfactory
D
Poor
Evidence
base
1
One or more level I
studies with a low risk of
bias or several level II
studies with a low risk of
bias
One or two level II studies
with a low risk of bias or
an SR/several level III
studies with a low risk of
bias
One or two level III studies with a low
risk of bias, or level I or II studies with
a moderate risk of bias
Level IV studies, or level 1 to II
studies/SRs with a high risk of bias
Consistency
2 All studies consistent Most studies consistent
and inconsistency may be
explained
Some inconsistency reflecting
genuine uncertainty around clinical
question
Evidence is consistent
Clinical impact Very large Substantial Moderate Slight or restricted
Generalisability Population/s studied in
body of evidence are the
same as the target
population in the
guideline
Population/s studied in
the body of evidence are
similar to the target
population for the
guideline
Population/s studied in the body of
evidence differ to the target
population guideline but it is clinically
sensible to apply this evidence to the
target population
3
Population/s studied in the body of
evidence differ to the target
population and hard to judge
whether it is sensible to generalize
to target population
Applicability Directly applicable to
Australian healthcare
context
Applicable to Australian
health care context with
few caveats
Probably applicable Australian
healthcare context with some caveats
Not applicable to Australian
healthcare context
SR = systematic review; several = more than two studies.
1 Level of evidence determined from the NHMRC Evidence Hierarchy.
2 If there is only one study, rank this component as ‘not applicable’.
3 For example, results in adults that are clinically sensible to apply to children OR psychosocial outcomes for one cancer that may be applicable to patients with
another cancer.
Table 2 Definition of NHMRC grades of recommendations
Grade of
recommendation
Description
A Body of evidence can be trusted to guide
practice
B Body of evidence can be trusted to guide
practice in most situations
C Body of evidence provides some support for
recommendation(s) but care should be taken in
its application
D Body of evidence is weak and recommendation
must be applied with caution
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invaluable in modifying FORM to be more effective and
useful.
The following issues were identified in the first con-
sultation and addressed in the second iteration of
FORM where appropriate:
￿ deciding between grades - but this has become
easier with time and familiarity
￿ determining and extracting relevant information
from synthesised sources (such as existing systematic
reviews) which are incompletely reported
￿ insufficient funding, human resources and/or time
for the rigorous systematic literature reviews needed
to underpin the evidence statements
￿ need to accommodate subjectivity in the interpre-
tation of the components and the final recommenda-
tion/s
In response to specific suggestions made in the first
consultation period, we made the following modifica-
tions to the FORM supporting documentation:
￿ revision of the notes, matrix and form to be more
user friendly
￿ the addition of ‘explanatory notes’ sections for
developers to document reasons for particular deci-
sions within the matrix
￿ the addition of a ‘dissenting opinions’ and ‘unre-
solved issues’ sections to the Evidence Statement
Form to keep decision making transparent and
informed
￿ a flowchart to assist in navigation
Feedback from the second stage of consultation
showed that the modifications were a major improve-
ment and that guideline developers agreed that the
FORM system of grading was an improvement on the
previous system where recommendations were ‘graded’
according to the level of evidence from the NHMRC
evidence hierarchy [3,6]. They also reported that the fra-
mework offers an opportunity to develop guidelines that
improve dissemination and uptake in clinical practice.
With increasing familiarity users have found the frame-
work fairly simple to use.
As methodological experts assisting guideline developers,
we have found the framework provides additional flexibil-
ity, especially when handling evidence with more than one
outcome measure (for example overall survival, pain, read-
mission rates). Variable results/evidence statements for
multiple outcomes can be captured by a single recommen-
dation. Furthermore, the framework also allows a recom-
mendation to be developed that balances the benefits and
harms of an intervention (i.e. safety and effectiveness), but
with enough flexibility to keep them separate if it is felt to
be important. More than 20 NHMRC guidelines have now
been completed using FORM.
Discussion
The formulation and inclusion of recommendations is
one of the defining differences between clinical practice
guidelines and other evidence syntheses such as sys-
tematic reviews. A recent review of the adequacy of
guideline recommendations has highlighted that over
half of the recommendations (52.7%) give no indication
of the strength of that recommendation [1].
The FORM process for formulation and grading of
recommendations in clinical practice guidelines is logi-
cal, simple to use and intuitive. Its concurrent develop-
ment with Australian levels of evidence [6] means that
NHMRC can provide Australian (and other) guideline
developers with an integrated framework for producing
high-quality recommendations that represent best-
practice and are implementable, acceptable and appro-
priate for the local health care system. The framework is
also generic - the same processes can be used to formu-
late and grade recommendations for any type of clinical
question, despite the differences in the type of evidence
required to address that question (e.g. questions of diag-
nostic test accuracy, risk factors for disease progression
or poor prognosis). Furthermore, health service provi-
ders can implement the evidence-based course of action
with appropriate modification in light of the individual
patient’s values and preferences.
In areas like public health where there may never be
high-level evidence supporting the use of different inter-
ventions, practice recommendations developed using other
grading systems would consistently rate a lower grade than
is felt appropriate by experts in those fields. Examples of
such areas include large-scale dietary questions, passive
smoking or exposure to environmental chemicals. This
does not occur using the FORM methodology. Using the
NHMRC levels of evidence for aetiology questions as an
alternative to the levels for intervention questions [6]
allows the evidence base component of our grading system
to be rated higher than would otherwise occur and this
would be reflected in the overall grade of recommendation.
The extensive pilot of FORM and subsequent uptake
by both new and experienced guideline developers has
shown that the framework is feasible and accepted. The
component approach allows transparency in how
recommendations are formulated, with users of the
guidelines able to explicitly see the various contributions
of factors such as quality of the evidence and clinical
impact. A further strength is that implementation and
resourcing issues are considered separately, which
means that effective but potentially costly interventions
are not penalised with a downgraded recommendation
Hillier et al. BMC Medical Research Methodology 2011, 11:23
http://www.biomedcentral.com/1471-2288/11/23
Page 6 of 8as the developers of this system felt that users’ willing-
ness to pay will vary according to the context of use.
Arguably the greater ability to differentiate strength of
recommendation (four levels) in FORM offers more pre-
cision for developers.
Limitations
The UK National Institute for Health and Clinical Excel-
lence (NICE) has decided to discontinue summary grades
for recommendations, on the grounds that their previous
grading system was being misinterpreted. They have sta-
ted that they are not sure that the GRADE system’s
approach to summary labels overcomes this [13]. We are
not aware of this sort of misinterpretation occurring with
FORM, and believe that the benefits of grading outweigh
the harms as clinicians are striving for clear-cut health
advice to assist with their individual decision-making.
However, ongoing monitoring and periodic review of the
application and use of FORM needs to be considered.
Recommendation formulation and grading can be par-
ticularly challenging when the evidence is scant and/or
poor, or conflicting. NICE has outlined some strategies
to address these challenges, including using consensus
when no evidence is found for a particular clinical ques-
tion and highlighting gaps in the evidence where evi-
d e n c ei ss c a n to rp o o r .[ 1 4 ]N I C Er e m i n d su st h a t
whenever guidelines are unable to rely on a solid evi-
dence base other methods used for formulating recom-
mendations must be transparent and set out clearly in
the guideline. A particular strength of an explicit pro-
cess such as FORM is that the path from evidence to
recommendation is made clear.
Current evidence frameworks are grappling with how
to integrate other forms of evidence needed to answer
qualitative questions such as optimal quality of life, and
we anticipate that FORM will need to be periodically
reassessed in the light of international debate about
levels of evidence and grading recommendations.
The purpose of clinical practice guidelines is to change
or guide health professionals’ behaviour and to improve
quality of care. Therefore, the ultimate test of guidelines
and the processes used to develop and implement guide-
lines will be improved health outcomes and improved
systems. One way of facilitating this is by developing
recommendations that are transparently produced
through a process that is user-friendly, weighs up multi-
ple concepts when formulating a course of action (much
as the clinician does for an individual patient), and pro-
vides clear advice on the confidence or uncertainty asso-
ciated with the recommended course of action.
Conclusion
FORM provides a contemporary and internationally relevant
structure within which clinical guideline developers can
consider current literature related to specific clinical ques-
tions. It has been developed through a unique partnership of
government, academic, private consultancy and clinical per-
sonnel with considerable experience in evidence-based prac-
tice and development of clinical practice guidelines. Our
work with over 20 guideline developers during the piloting
of the FORM process has demonstrated it to be a logical,
simple to use and intuitive system for formulating and grad-
ing recommendations in clinical practice guidelines.
Appendix 1
History of NHMRC Guidelines Assessment Register
(GAR) and members of the Levels and Grades Working
Party
In 2002, the NHMRC convened a register of methodo-
logical experts (Guidelines Assessment Register [GAR])
to assist external guideline developers in Australia
through the process of identifying and synthesising evi-
dence for guidelines in a way that complied with
NHMRC specified requirements and would assist them
in gaining NHMRC endorsement for their work. The
main role of the GAR consultants was to oversee the
methodological processes in external development of
guidelines, particularly reviewing and classifying the qual-
ity of the evidence, and how these classifications corre-
lated to the resultant recommendations. The expected
outcome of the involvement of the GAR consultants was
that consistently high quality guidelines would be sub-
mitted to HAC for approval, and that problems identified
post hoc in guideline development could be pre-empted.
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Technology Analysts Pty Ltd)
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Allied Health Evidence, University of South Australia)
Tracy Merlin (Adelaide Health Technology Assess-
ment, Discipline of Public Health, University of
Adelaide)
Philippa Middleton, Rebecca Tooher (ARCH, Univer-
sity of Adelaide)
Janet Salisbury (Biotext Pty Ltd)
Additional material
Additional file 1: NHMRC Evidence Statement (landscape Document).
This file includes the FORM documents discussed - the matrix and
trigger questions for guideline developers to complete the Evidence
Statement.
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